275 related articles for article (PubMed ID: 23554887)
1. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
[TBL] [Abstract][Full Text] [Related]
2. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
3. Mu and delta opioid receptor knockout mice show increased colonic sensitivity.
Reiss D; Ceredig RA; Secher T; Boué J; Barreau F; Dietrich G; Gavériaux-Ruff C
Eur J Pain; 2017 Apr; 21(4):623-634. PubMed ID: 27748566
[TBL] [Abstract][Full Text] [Related]
4. FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR-DOR Heteromer.
Akgün E; Lunzer MM; Tian D; Ansonoff M; Pintar J; Bruce D; Hawkinson JE; Wilcox GL; Portoghese PS
Biochemistry; 2021 May; 60(18):1413-1419. PubMed ID: 32930576
[TBL] [Abstract][Full Text] [Related]
5. Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon.
DiCello JJ; Carbone SE; Saito A; Rajasekhar P; Ceredig RA; Pham V; Valant C; Christopoulos A; Veldhuis NA; Canals M; Massotte D; Poole DP
Cell Mol Gastroenterol Hepatol; 2020; 9(3):465-483. PubMed ID: 31759144
[TBL] [Abstract][Full Text] [Related]
6. Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation.
He SQ; Zhang ZN; Guan JS; Liu HR; Zhao B; Wang HB; Li Q; Yang H; Luo J; Li ZY; Wang Q; Lu YJ; Bao L; Zhang X
Neuron; 2011 Jan; 69(1):120-31. PubMed ID: 21220103
[TBL] [Abstract][Full Text] [Related]
7. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
8. Evidence and Function Relevance of Native DOR-MOR Heteromers.
Cahill CM; Ong E
Handb Exp Pharmacol; 2018; 247():115-127. PubMed ID: 29633181
[TBL] [Abstract][Full Text] [Related]
9. Opioid receptor heteromers in analgesia.
Costantino CM; Gomes I; Stockton SD; Lim MP; Devi LA
Expert Rev Mol Med; 2012 Apr; 14():e9. PubMed ID: 22490239
[TBL] [Abstract][Full Text] [Related]
10. Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.
Brissett DI; Whistler JL; van Rijn RM
Eur J Pain; 2012 Mar; 16(3):327-37. PubMed ID: 22337177
[TBL] [Abstract][Full Text] [Related]
11. Heteromer Induction: An Approach to Unique Pharmacology?
Portoghese PS; Akgün E; Lunzer MM
ACS Chem Neurosci; 2017 Mar; 8(3):426-428. PubMed ID: 28139906
[TBL] [Abstract][Full Text] [Related]
12. Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.
Schuster DJ; Metcalf MD; Kitto KF; Messing RO; Fairbanks CA; Wilcox GL
Br J Pharmacol; 2015 Jan; 172(2):642-53. PubMed ID: 24827408
[TBL] [Abstract][Full Text] [Related]
13. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
14. Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.
Harvey JH; Long DH; England PM; Whistler JL
ACS Med Chem Lett; 2012 Aug; 3(8):640-644. PubMed ID: 23585918
[TBL] [Abstract][Full Text] [Related]
15. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
16. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Neurochem; 2008 May; 105(3):865-73. PubMed ID: 18182056
[TBL] [Abstract][Full Text] [Related]
18. Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.
Gendron L; Pintar JE; Chavkin C
Neuroscience; 2007 Dec; 150(4):807-17. PubMed ID: 17997230
[TBL] [Abstract][Full Text] [Related]
19. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
Lei W; Vekariya RH; Ananthan S; Streicher JM
J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
[TBL] [Abstract][Full Text] [Related]
20. Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.
Moreno E; Quiroz C; Rea W; Cai NS; Mallol J; Cortés A; Lluís C; Canela EI; Casadó V; Ferré S
J Neurosci; 2017 Feb; 37(5):1176-1186. PubMed ID: 28007761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
